filmov
tv
Researcher comment: The VERTIS-CV trial | Chris Cannon
Показать описание
Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).
0:07:17
0:10:11
0:08:09
0:25:49
0:16:07
0:05:09
0:09:50
0:05:12
0:26:43
0:42:35
1:02:26
1:10:24
0:35:59
1:12:21
0:35:45
1:26:29
1:23:06
0:35:45
0:54:54
1:06:58
0:05:12
0:05:25
0:56:47
0:03:07